BMO Capital Maintains Outperform on Eli Lilly, Raises Price Target to $865
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has maintained an Outperform rating on Eli Lilly (NYSE:LLY) and increased the price target from $710 to $865, indicating a positive outlook on the company's stock.
February 07, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Evan Seigerman has reaffirmed an Outperform rating on Eli Lilly and raised the price target from $710 to $865.
The increase in price target by a reputable analyst suggests a strong bullish sentiment towards Eli Lilly's stock. This is likely to positively influence investor perception and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100